SuperworthNeurogene shares outstanding NGNE
Diluted shares outstanding, averaged over each quarter, from 2013.
- Latest quarter, to Jun 30, 2026
- 22.6M
- On a year earlier
- +7.1%
- more shares
Neurogene had 22.6M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 7.1% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 22.1M | +13% |
| FY2024 | 19.5M | +604% |
| FY2022 | 2.8M | +0% |
| FY2021 | 2.8M | +1% |
| FY2020 | 2.7M | +57% |
| FY2019 | 1.7M | +48% |
| FY2018 | 1.2M | +0% |
| FY2017 | 1.2M | +0% |
| FY2016 | 1.2M | +36% |
| FY2015 | 860.6K | +61% |
| FY2014 | 534.8K | +3444% |
| FY2013 | 15.1K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 22.6M | +7% | |
| Q1 FY26 | 22.3M | +6% | |
| Q4 FY25 | 22.1M | +13% | |
| Q3 FY25 | 21.2M | +25% | |
| Q2 FY25 | 21.1M | +24% | |
| Q1 FY25 | 21M | +24% | |
| Q4 FY24 | 19.5M | n/a | |
| Q3 FY24 | 17M | +3699% | |
| Q2 FY24 | 16.9M | +3712% | |
| Q1 FY24 | 16.9M | +510% | |
| Q3 FY23 | 446.3K | −84% | |
| Q2 FY23 | 444.5K | −84% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Neurogene
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.